Search results
Showing 61 to 75 of 692 results for innovative
In development [GID-TA11503] Expected publication date: 10 September 2025
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for treating advanced (unresectable or metastatic) melanoma in adults.
Midostaurin for treating advanced systemic mastocytosis (TA728)
Evidence-based recommendations on midostaurin (Rydapt) for treating advanced systemic mastocytosis in adults.
we do NICE has a key role in the evaluation of and access to new and innovative medicines and treatments for the health system, playing...
His role is all about getting to grips with complex problems and finding innovative solutions. Developing careers Jose takes us through
Evidence-based recommendations on eribulin (Halaven) for locally advanced or metastatic (secondary) breast cancer in adults who have had 2 or more courses of chemotherapy.
Guidance Executive
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)
Evidence-based recommendations on pegylated liposomal irinotecan (Onivyde) for treating pancreatic cancer in adults.
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)
Evidence-based recommendations on ramucirumab (Cyramza) for locally advanced or metastatic non-small-cell lung cancer in adults who have had platinum-based chemotherapy.
How to submit a new medical technology to NICE for guidance
Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)
Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease in adults.
Evidence-based recommendations on autologous chondrocyte implantation using chondrosphere (Spherox) for treating symptomatic articular cartilage defects of the knee in adults.
A joint NICE and NHS England meeting can help to ensure you're ready for NHS patient access and subsequent NICE appraisal
In development [GID-TA11289] Expected publication date: TBC
In development [GID-TA10912] Expected publication date: 16 July 2025